Pharmafile Logo

News and Press Releases

FLAMOD against respiratory infections: phase I clinical trial of innovative new drug begins

20 March 2025 -- Lausanne, Switzerland -- A phase I clinical trial for a groundbreaking therapeutic innovation against respiratory infections has begun at the Clinical Investigation Centre of the Academic...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

European Respiratory Society
4, Avenue Ste-Luce CH 1003 Lausanne Switzerland

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 20, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials

This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes’ role in the industry’s transformation Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise to...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 19, 2025

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Advarra Unveils Oncology Research Pulse

Content-driven program brings together clinical trial stakeholders to foster knowledge sharing and collaboration in cancer research 12 March 2025 -- Maryland, US -- Advarra, the market leader in regulatory review...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 12, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Combination of complete skin clearance data and favourable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (Pso) treated with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

10 March 2025 -- London, UK and New York, US -- OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Innovaderm Research Rebrands as Indero, a dual-focus CRO 

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero
3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years 

The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...

Category: Other, Pharmaceutical
Posted: March 6, 2025

Octapharma
Glassworks House 32 Shudehill Manchester M4 1EZ

Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union

4 March 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Centauri
info@centauritherapeutics.com
Discovery Park, Sandwich CT13 9ND

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. 4 March 2025 -- Texas, US -- FibroBiologics, Inc, a clinical-stage biotechnology...

Category: Biotechnology, Other, Pharmaceutical
Posted: March 4, 2025

FibroBiologics
info@fibrobiologics.com
455 E. Medical Center Blvd. Suite 300 Houston, TX 77598